Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes
Latest Information Update: 16 Jan 2024
At a glance
- Drugs Dulaglutide (Primary) ; Nisotirostide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 10 Jan 2024 Status changed from active, no longer recruiting to completed.
- 19 Oct 2023 Planned End Date changed from 6 Dec 2023 to 22 Nov 2023.
- 19 Oct 2023 Planned primary completion date changed from 6 Dec 2023 to 22 Nov 2023.